Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 04:49 am EDT
Share
Medy-Tox Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported negative sales was KRW 0.0003 million compared to KRW 0.00017 million a year ago. Net income was KRW 8,565.72 million compared to KRW 19,234.34 million a year ago. Basic earnings per share from continuing operations was KRW 1,273 compared to KRW 3,044.7619 a year ago. Diluted earnings per share from continuing operations was KRW 1,274 compared to KRW 3,020 a year ago. Basic earnings per share was KRW 1,273 compared to KRW 3,197 a year ago. Diluted earnings per share was KRW 1,274 compared to KRW 3,171 a year ago.
For the six months, sales was KRW 0.00027 million compared to negative sales of KRW 0.00004 million a year ago. Net income was KRW 14,125.67 million compared to KRW 24,283.7 million a year ago. Basic earnings per share from continuing operations was KRW 1,973 compared to KRW 3,687.619 a year ago. Diluted earnings per share from continuing operations was KRW 1,973 compared to KRW 3,659.0476 a year ago. Basic earnings per share was KRW 1,973 compared to KRW 3,872 a year ago.
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
MEDY-TOX INC. 
